血管生成
医学
癌症研究
川地31
免疫疗法
乳腺癌
免疫组织化学
癌症
体内
免疫系统
肿瘤浸润淋巴细胞
流式细胞术
重组DNA
免疫学
生物
内科学
生物技术
基因
生物化学
作者
Azadeh Sharif Khatibi,Nasim Hayati Roodbari,Keivan Majidzade-A,Parichehreh Yaghmaei,Leila Farahmand
出处
期刊:Immunotherapy
[Future Medicine]
日期:2019-12-01
卷期号:11 (18): 1555-1567
被引量:13
标识
DOI:10.2217/imt-2019-0068
摘要
Aim: Achievements in cancer immunotherapy require augmentation of a host's anti-tumor immune response for anti-cancer modality. Materials & methods: Different concentrations of recombinant anti-CD3 nanobody were administered at predetermined time intervals during a 24-day treatment period and then expression of angiogenic biomarkers including VEGFR2, MMP9 and CD31, as well as tumor cell proliferation marker ki67, was determined in tumor sections by immunohistochemistry. Furthermore, expression of cytokines was examined in peripheral blood of mice. Results: Based on our results, administration of nanobody could reduce biomarker expression in tumor sections. Tumor growth was also delayed and survival rate was increased in response to nanobody treatment. Moreover, expression of pro-inflammatory cytokines was reduced. Conclusion: In conclusion, we demonstrated that administration of nanobody could effectively suppress angiogenesis as well as tumor growth.
科研通智能强力驱动
Strongly Powered by AbleSci AI